The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection

Journal of Infection and Chemotherapy

Volumn 18, Issue 2, 2012, Pages 241-246

  Yamamoto, Yoshihiro ^a   Izumikawa, Koichi ^a   Hashiguchi, Koji ^b   Fukuda, Yuichi ^c   Kobayashi, Tsutomu ^d   Kondo, Akira ^e   Inoue, Yuichi ^e   Morinaga, Yoshitomo ^f   Nakamura, Shigeki ^a   Imamura, Yoshifumi ^a   Miyazaki, Taiga ^a   Kakeya, Hiroshi ^a   Yanagihara, Katsunori ^f   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b JAPANESE RED CROSS NAGASAKI GENBAKU HOSPITAL   (Japan)

^c Sasebo Shiritsu Sogo Hospital   (Japan)

^d SASEBO CHUO HOSPITAL   (Japan)

^e Isahaya Health Insurance General Hospital   (Japan)

^f NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Arbekacin; Methicillin resistant Staphylococcus aureus; Pneumonia; Sepsis

Indexed keywords

ANTIINFECTIVE AGENT; HABEKACIN;

AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PNEUMONIA; SEPSIS; UNSPECIFIED SIDE EFFECT;

EID: 84863326417     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0397-4     Document Type: Article

References (14)

1. Saito A, Miki F, Oizumi K, Rikitomi N, Watanabe A, Koga H, et al. Report: Clinical evaluation methods for new antimicrobial agents for the treatment of respiratory tract infections. Jpn J Chemother 1997;45:762-78 (in Japanese).
2. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788-94.
3. Japan Nosocomial Infection Surveillance (Internet) Japan; (cited 01 Nov 2011). Available from: http://www.nih-janis.jp/report/ open-report/2010/3/2/zen- Open-Report-201000.pdf.
4. Kurazono M, Yamada K., Hirai Y, Ida T, Inoue M. Epidemiological survey of drug resistance of methicillin-resistant Staphylococcus aureus isolated in Japan in 2000. Jpn J Chemother 2002;50:494-9 (in Japanese).
5. Watanabe T, Ohashi K, Matsui K, Kubota T. Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1997;39:471-6.
6. LaPlante KL, Rybak MJ. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn Microbiol Infect Dis. 2004;50:125-30.
7. Yokoyama K, Doi Y, Yamane K, Kurokawa H, Shibata N, Shibayama K, et al. Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet. 2003;362:1888-93.
8. Fujimura S, Gomi K, Takane H, Nakano Y, Fuse K, Kikuchi T, et al. Susceptibility to arbekacin of clinical strains of Pseudomonas aeruginosa isolated in the Tohoku area between 2003 and 2007. Jpn J Chemother 2009;57:91-6 (in Japanese).
9. Zapor MJ, Barber M, Summers A, Miller GH, Feeney LA, Eberly LE, et al. In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center. Antimicrob Agents Chemother. 2010;54:3015-7.
10. Aikawa N, Kohno S, Kaku M, Watanabe A, Yamaguchi K, Tanigawara Y. An open clinical study of arbekacin 200 mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA): a clinical pharmacology study. Jpn J Chemother 2008;56:299-312 (in Japanese).
11. Kawano H, Tanigawara Y. Postmarketing surveillance review of arbekacin sulfate in patients with therapeutic drug monitoring. Jpn J Ther Drug Monit 2010;27:55-71 (in Japanese).
12. Tanikaze N, Komatsu M, Shimakawa K, Yamamoto I. Study of clinical significance of PK/PD (pharmacokinetic/pharmacodynamic) parameters after administering arbekacin to patients with pulmonary methicillin-resistant Staphylococcus aureus infection. Jpn J Chemother 2004;52:469-73 (in Japanese).
13. Sato R, Tanigawara Y, Kaku M, Aikawa N, Shimizu K. Pharmacokinetic- pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50: 3763-9.
14. Tanigawara Y, Sato R, Morita K, Kaku M, Aikawa N, Shimizu K. Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:3754-62.